BACKGROUND: Molecular imaging of dopaminergic parameters has contributed to the dopamine hypothesis of schizophrenia, expanding our understanding of pathophysiology, clinical phenomenology and treatment. Our aim in this study was to compare (18)F-fallypride binding potential BP(ND) in a group of patients with schizophrenia-spectrum illness vs. controls, with a particular focus on the cortex and thalamus. METHODS: We acquired (18)F-fallypride positron emission tomography images on 33 patients with schizophrenia spectrum disorder (28 with schizophrenia; 5 with schizoaffective disorder) and 18 normal controls. Twenty-four patients were absolutely neuroleptic naïve and nine were previously medicated, although only four had a lifetime neuroleptic exposure of greater than two weeks. Parametric images of (18)F-fallypride BP(ND) were calculated to compare binding across subjects. RESULTS: Decreased BP(ND) was observed in the medial dorsal nucleus of the thalamus, prefrontal cortex, lateral temporal lobe and primary auditory cortex. These findings were most marked in subjects who had never previously received medication. CONCLUSIONS: The regions with decreased BP(ND) tend to match brain regions previously reported to show alterations in metabolic activity and blood flow and areas associated with the symptoms of schizophrenia. (c) 2010 Elsevier B.V. All rights reserved.
BACKGROUND: Molecular imaging of dopaminergic parameters has contributed to the dopamine hypothesis of schizophrenia, expanding our understanding of pathophysiology, clinical phenomenology and treatment. Our aim in this study was to compare (18)F-fallypride binding potential BP(ND) in a group of patients with schizophrenia-spectrum illness vs. controls, with a particular focus on the cortex and thalamus. METHODS: We acquired (18)F-fallypride positron emission tomography images on 33 patients with schizophrenia spectrum disorder (28 with schizophrenia; 5 with schizoaffective disorder) and 18 normal controls. Twenty-four patients were absolutely neuroleptic naïve and nine were previously medicated, although only four had a lifetime neuroleptic exposure of greater than two weeks. Parametric images of (18)F-fallypride BP(ND) were calculated to compare binding across subjects. RESULTS: Decreased BP(ND) was observed in the medial dorsal nucleus of the thalamus, prefrontal cortex, lateral temporal lobe and primary auditory cortex. These findings were most marked in subjects who had never previously received medication. CONCLUSIONS: The regions with decreased BP(ND) tend to match brain regions previously reported to show alterations in metabolic activity and blood flow and areas associated with the symptoms of schizophrenia. (c) 2010 Elsevier B.V. All rights reserved.
Authors: J Delforge; M Bottlaender; C Loc'h; I Guenther; C Fuseau; B Bendriem; A Syrota; B Mazière Journal: J Cereb Blood Flow Metab Date: 1999-05 Impact factor: 6.200
Authors: Jogeshwar Mukherjee; Bradley T Christian; Kelly A Dunigan; Bingzhi Shi; Tanjore K Narayanan; Martin Satter; Joseph Mantil Journal: Synapse Date: 2002-12-01 Impact factor: 2.562
Authors: Neeltje E M van Haren; Hilleke E Hulshoff Pol; Hugo G Schnack; Wiepke Cahn; René C W Mandl; D Louis Collins; Alan C Evans; René S Kahn Journal: Neuropsychopharmacology Date: 2007-02-28 Impact factor: 7.853
Authors: Heli Tuppurainen; Jyrki T Kuikka; Mikko P Laakso; Heimo Viinamäki; Minna Husso; Jari Tiihonen Journal: Eur Arch Psychiatry Clin Neurosci Date: 2006-06-16 Impact factor: 5.270
Authors: Eduard Parellada; Francisco Lomena; Mireia Font; Deborah Pareto; Fernando Gutierrez; Marc Simo; Emili Fernández-Egea; Javier Pavia; Domenec Ros; Miquel Bernardo Journal: Nucl Med Commun Date: 2008-10 Impact factor: 1.690
Authors: Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham Journal: Biol Psychiatry Date: 2016-03-31 Impact factor: 13.382
Authors: Pontus Plavén-Sigray; Pauliina Ikonen Victorsson; Alexander Santillo; Granville J Matheson; Maria Lee; Karin Collste; Helena Fatouros-Bergman; Carl M Sellgren; Sophie Erhardt; Ingrid Agartz; Christer Halldin; Lars Farde; Simon Cervenka Journal: Mol Psychiatry Date: 2021-11-10 Impact factor: 13.437
Authors: Kavya Prasad; Erik F J de Vries; Philip H Elsinga; Rudi A J O Dierckx; Aren van Waarde Journal: Int J Mol Sci Date: 2021-02-09 Impact factor: 5.923